NASDAQ · NITO
Basic Materials · Agricultural Inputs
$3.06
Down-$0.58 (-15.93%)
Updated Aug 15, 2026, 2:34 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NITO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning NITO.
NITO research
Company profile and research snapshot.
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 25, 2026
N2OFF, Inc. (NASDAQ: NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive
Yahoo · Feb 12, 2026
MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty
Benzinga · Feb 12, 2026
MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030Neve Yarak, Israel,
Yahoo · Feb 2, 2026
Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NITO.
